Metzelder, S K
Michel, C
von Bonin, M
Rehberger, M
Hessmann, E
Inselmann, S
Solovey, M
Wang, Y
Sohlbach, K
Brendel, C
Stiewe, T
Charles, J
Ten Haaf, A
Ellenrieder, V
Neubauer, A
Gattenlöhner, S
Bornhäuser, M
Burchert, A
Article History
Received: 9 February 2015
Revised: 31 March 2015
Accepted: 1 April 2015
First Online: 14 April 2015
Competing interests
: AB received funding from Bayer Healthcare in support of the SORMAIN trial, which is testing sorafenib maintenance therapy after allogeneic stem cell transplantation in FLT3-ITD+ AML (EudraCT 2010-018539-16). The remaining authors declare no conflict of interest.